Doripenem: A new carbapenem antibiotic

Chahine, Elias B.; Ferrill, Mary J.; Poulakos, Mara N.
December 2010
American Journal of Health-System Pharmacy;12/1/2010, Vol. 67 Issue 23, p1215
Academic Journal
Purpose. The chemistry, pharmacology, antimicrobial activity, pharmacokinetics, pharmacodynamics, efficacy and safety in humans, and formulary considerations of doripenem are reviewed. Summary. Doripenem, a member of the β-lactam class of antibiotics, is the newest addition to the carbapenems. It exhibits concentration-independent bactericidal activity against gram-positive bacteria; enteric and nonenteric gram-negative bacteria, including extended-spectrum β-lactamase-producing strains; and anaerobic pathogens. Doripenem was found to be noninferior to meropenem in the treatment of complicated intraabdominal infections and noninferior to levofloxacin in the treatment of complicated urinary tract infections including pyelonephritis and was granted marketing approval by the Food and Drug Administration for these two indications. Doripenem was also found to be noninferior to imipenem in the treatment of ventilator-associated pneumonia and noninferior to piperacillin--tazobactam in the treatment of hospital-acquired pneumonia. It has a favorable safety profile, with gastrointestinal complaints and headache being the most common adverse effects and allergic reactions the most serious adverse effects. Doripenem has a relatively low potential to induce seizures. The only known clinically relevant drug interaction is that coadministration with valproic acid may result in reductions of valproic acid serum concentrations. As with most renally eliminated antibiotics, the dose of doripenem should be adjusted according to kidney function. Conclusion. Doripenem is an injectable carbapenem antibiotic with a spectrum of activity comparable to that of imipenem and meropenem. Its safety is similar to that of other carbapenems.


Related Articles

  • INFECTIOUS DISEASES. Rawlins, Matthew // Journal of Pharmacy Practice & Research;Mar2011, Vol. 41 Issue 1, p65 

    The article presents abstracts related to infectious diseases including one on tigecycline versus imipenem/cilastatin for hospital acquired pneumonia, one on pre-exposure prophylaxis to prevent HIV and one on cranberry juice and recurrent urinary tract infections.

  • Outcome of Antimicrobial Therapy of Pediatric Urinary Tract Infections Caused by Extended-Spectrum β-Lactamase-Producing Enterobacteriaceae. Bongjin Lee; Soo Young Kang; Hyun Mi Kang; Nu Ri Yang; Hee Gyung Kang; Il Soo Ha; Hae Il Cheong; Hoan Jong Lee; Eun Hwa Choi // Infection & Chemotherapy;Dec2013, Vol. 45 Issue 4, p415 

    Background: The purpose of this study was to compare the outcome of carbapenem versus non-carbapenem antimicrobial therapy for pediatric urinary tract infections (UTIs) caused by extended-spectrum β-lactamase (ESBL) producing Enterobacteriaceae. Materials and Methods: From 2006 to 2011, 42...

  • Naltrexone in the treatment of opioid dependence. George, Sanju; Ekhtiari, Hamed // British Journal of Hospital Medicine (17508460);Oct2010, Vol. 71 Issue 10, p568 

    Naltrexone is an opioid antagonist that acts by preventing the reinforcing effects of addictive opioids. This article provides an overview of naltrexone, its pharmacology, treatment effectiveness and role as a relapse prevention agent in the treatment of opioid dependence.

  • Lumiracoxib + fluconazole: no significant interaction.  // Reactions Weekly;2/21/2004, Issue 989, p3 

    Discusses research being done on the pharmacokinetic and pharmacodynamic profile of lumiracoxib when coadministered with fluconazole. Reference to a study by G. Scott et al, published in the February 2004 issue of the "Journal of Clinical Pharmacology"; Doses of lumiracoxib and fluconazole...

  • Levofloxacin weight-adjusted dosing and pharmacokinetic disposition in a morbidly obese patient. Luque, Sonia; Grau, Santiago; Valle, Marta; Colino, Clara Isabel; Ferrer, Antoni // Journal of Antimicrobial Chemotherapy (JAC);Jul2011, Vol. 66 Issue 7, p1653 

    The article discusses the pharmacokinetic/pharmacodynamic parameters of levofloxacin in a patient with severe morbid obesity. It notes that levofloxacin was administered at an actual body weight-adjusted dose of 4 milligrams/kilogram (mg/kg)/12 hours (h). It reports that renal function improved...

  • NEW PRODUCTS.  // MPR - Nurse Practitioners' Edition;Fall2013, Vol. 20 Issue 3, pA14 

    The article offers information on several drugs including Giazo, Belviq and Kazano. It states that Belviq which contains Balsalazide disodium is an U.S. Food & Drug Administration (FDA)-approved medication, used in treatment of mildly to moderately active Ulcerative Colitis. It further mentions...

  • Tumour necrosis factor (TNF) inhibitors are an effective option in the management of Crohn's disease.  // Drugs & Therapy Perspectives;Sep2010, Vol. 26 Issue 9, p15 

    The aim of management of Crohn's disease is to reduce the impact of the disease. However, symptom control is not sufficient to avoid the complications of Crohn's disease, thus necessitating the introduction of stricter treatment goals, including mucosal healing. The optimal utilization of tumour...

  • Tetracyclines, including subantimicrobial-dose doxycycline, are effective options for the treatment of rosacea.  // Drugs & Therapy Perspectives;Sep2010, Vol. 26 Issue 9, p19 

    Antimicrobial dosages of tetracyclines are effective in the treatment of rosacea, but their long-term use is associated with concerns. Doxycycline at the recently approved sub-antimicrobial dosage of 40 mg/day provides acceptable tolerability, allows for long-term therapy and does not appear to...

  • High-Dose, Extended-Interval Colistin Administration in Critically Ill Patients: Is This the Right Dosing Strategy? A Preliminary Study. Dalfino, Lidia; Puntillo, Filomena; Mosca, Adriana; Monno, Rosa; Spada, Maria Luigia; Coppolecchia, Sara; Miragliotta, Giuseppe; Bruno, Francesco; Brienza, Nicola // Clinical Infectious Diseases;Jun2012, Vol. 54 Issue 12, p1720 

    In critically ill patients with otherwise untreatable nosocomial infection due to gram-negative bacteria susceptible only to colistin, a high-dose, extended-interval colistin dosing regimen is, according to the pharmacokinetic/pharmacodynamic behavior of the drug, associated with low renal...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics